Hereditary Angioedema – Epidemiology – Europe

Clarivate Epidemiology’s coverage of hereditary angioedema (HAE) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of HAE for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s HAE forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HAE over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following patient populations:

  • Diagnosed prevalent cases of HAE.
  • Diagnosed prevalent cases of HAE type 1.
  • Diagnosed prevalent cases of HAE type 2.
  • Diagnosed prevalent cases of HAE type 3.

Note: Coverage may vary by country.